TX-MARY-KAY
20.12.2019 00:08:07 CET | Business Wire | Press release
Mary Kay Inc. continues to make its mark on the beauty industry through its ongoing partnerships with Ukrainian and Belarus Fashion Weeks, Mercedes-Benz Fashion Week Russia, and Bratislava Fashion Days in Slovakia and Czech Republic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005838/en/
“As an innovator of beauty trends, Mary Kay along with beauty artists, unveiled 2020 runway looks throughout fashion weeks in Europe,” stated Tara Eustace, President of Mary Kay for the European Region. “The runways at fashion week are the perfect stage to share inspiration, debut our innovations with the fashion world and elevate makeup trends in each of these countries.”
Designers, influencers, celebrities, makeup artists, beauty bloggers and editors attended all five events where Mary Kay was the official beauty partner for the spring/summer 2020 fashion week season.
“The Mary Kay Global Design Studio was created over 10 years ago to inspire beauty trends and drive innovation, fueling creativity and individuality through fashion collaborations around the world,” said Sheryl Adkins-Green, Chief Marketing Officer, and Creative & Inspiration Officer for the Mary Kay Global Design Studio. “During fashion weeks, makeup artists in collaboration with Mary Kay, unleashed some of the major trends of the season. Beauty enthusiasts can get the look ‘as seen’ on the runway or revisit the inspiration to create their own.”
Fashion Weeks Highlights:
Held in Kyiv between August 31-September 4, 2019, Ukrainian Fashion Week (UFW) kicked off the Mary Kay sponsored events in Europe. Under the artistic direction of lead makeup artist MartElle, a team of 40 beauty artists, all of whom are also members of the Mary Kay independent sales force, prepped the runway models for 30 Ukrainian designers and performed 350 different makeup looks throughout UFW. One of the fashion shows was an exclusive capsule pink bra collection collaboration between Mary Kay Ukraine and lingerie brand Keòsme aimed at supporting women diagnosed with breast cancer. Ten percent of sales proceeds from the exclusive collection will be donated to a Ukrainian nonprofit organization that promotes female health and wellness.
Bratislava Fashion Days by Mercedes-Benz was next in Bratislava on September 16-19, and Prague on October 5-6. For the second year in a row, Mary Kay Slovakia was the Official Makeup Artist for the event. Makeup artists prepared the show-stopping makeup looks worn by runway models and starred in the backstage stories on Fashion TV. Inspired by Mary Kay’s Global Beauty Ambassador Luis Casco , the “Sparkling Pewter,” “Sultry Glam,” “Sweet Champagne,” and “Garnet Gold” special looks became the highlights of the shows. The December 17 show in Bratislava marked the closing of the 2019 edition of the Fashion Days.
Mary Kay Russia has been the Official Makeup Artist of the Mercedes-Benz Fashion Week Russia (MBFW Russia) for 7 years in a row—13 consecutive seasons. The largest fashion event in Eastern Europe, MBFW Russia was held in Moscow on October 15-19. Luis Casco, and star makeup artist Andrey Shilkov, co-created the looks for 109 shows out of a total of 119, while a makeup team from the Mary Kay Russia independent sales force represented the brand backstage. The stunning beauty look imagined for the Te Amo Couture runway show was the result of the exclusive Casco-Shilkov collaboration.
The Belarus Fashion Week (BFW) held in Minsk on October 17- 20, 2019, wrapped up a successful fashion week season for Mary Kay in Eastern Europe. Mary Kay was BFW Official Makeup Artist for the 7th season in a row. A team of beauty artists from the Mary Kay Belarus independent sales force featured 650 runway looks and no less than 500 makeovers under the guidance of beauty artist maestro Alexander Kiryniuk, who also presented the season's trends.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191219005838/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom